华兰生物 (002007.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

27.7x

EV/EBITDA

16.5x

Market Cap

CNY 23.44B

MomentumView details →

1D Return

−2.51%

YTD Return

−13.81%

RSI (14)

47.1

ValuationView details →

P/E (Fwd)

27.7x

EV/EBITDA

16.5x

Market Cap

CNY 23.44B

RSI (14)

47.1

MomentumView details →

1D Return

−2.51%

YTD Return

−13.81%

ProfitabilityView details →

Gross Margin

56.52%

Net Margin

19.10%

EBITDA Margin

33.62%

ROE (TTM)

7.32%

ROA (TTM)

5.70%

Asset Turnover

0.30x

GrowthView details →

Revenue YoY

+0.67%

EPS YoY

−24.74%

FCF YoY

+66.39%

Revenue CAGR 3Y

+0.57%

EPS CAGR 3Y

−4.41%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.08

EPS Surprise

−27.25%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.13

Avg Surprise (4Q)

−27.25%

Rev Surprise

−6.92%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

6.57x

Quick Ratio

4.65x

Div Yield

7.67%

Div Rate

CNY 1.00

Div Growth 1Y

−28.57%

Financials snapshotView financials →

Revenue (TTM)

4.49B

Net Income (TTM)

857.61M

Op. CF (TTM)

857.39M

Next earningsNov 2, 2026 →

Latest newsMore news →

Hualan Biological reported first-half revenue of 1.57 billion RMB and net profit of 383.4 million RMB.8d ago

Hualan Biological's controlling subsidiary Hualan Vaccine is conducting research and development of a novel influenza virus mRNA vaccine.26d ago

Similar companies

航发控制000738.SZ 丽珠集团000513.SZ 尚太科技001301.SZ 广电运通002152.SZ 晶澳科技002459.SZ 托伦斯301583.SZ Find similar companies →

Latest newsMore news →

Hualan Biological reported first-half revenue of 1.57 billion RMB and net profit of 383.4 million RMB.8d ago Hualan Biological's controlling subsidiary Hualan Vaccine is conducting research and development of a novel influenza virus mRNA vaccine.26d ago